RVNC Revance Therapeutics Inc.

11.34
+0.44  (+4%)
Previous Close 10.9
Open 10.96
Price To Book 2.65
Market Cap 500,122,713
Shares 44,102,532
Volume 545,214
Short Ratio
Av. Daily Volume 458,226

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 completion of enrolment due 4Q 2019.
DAXI (RT002)
Plantar fasciitis
Phase 2 top-line data due 1H 2020.
DAXI (RT002)
Lateral Canthal (Crow’s Feet) Lines
Phase 3 completion of enrolment due 4Q 2019.
DAXI (RT002) - ASPEN
Cervical dystonia
BLA filing due fall of 2019.
DAXI (RT002)
Moderate to severe glabellar (frown) lines
Phase 2 trial to be initiated in 2020.
DAXI (RT002)
Chronic migraine
Phase 2 completion of enrolment due 1H 2020.
DAXI (RT002)
Upper limb spasticity
Phase 2 top-line data due 1H 2020.
DAXI (RT002)
Forehead lines

Latest News

  1. Edited Transcript of RVNC earnings conference call or presentation 5-Aug-19 8:30pm GMT
  2. Revance Therapeutics (RVNC) Q2 2019 Earnings Call Transcript
  3. Revance Reports Second Quarter 2019 Financial Results, Provides Corporate Update
  4. Revance Therapeutics, Inc. to Host Earnings Call
  5. Revance to Release Second Quarter 2019 Financial Results on Monday, August 5, 2019
  6. Will Revance Therapeutics (RVNC) Report Negative Q2 Earnings? What You Should Know
  7. Revance Adds Life Sciences Audit Executive Chris Nolet to Board of Directors
  8. Did Changing Sentiment Drive Revance Therapeutics's (NASDAQ:RVNC) Share Price Down A Worrying 59%?
  9. AbbVie (ABBV) Shares Down So Far This Year: Here's Why
  10. Is Revance Therapeutics Inc (RVNC) A Good Stock To Buy?
  11. Here's Why Nobody's Happy About This $63 Billion Buyout
  12. Revance Therapeutics (RVNC) Jumps: Stock Rises 5.2%
  13. Revance Adds Iconic Brand Builder Jill Beraud to Board of Directors
  14. Revance to Participate in the Goldman Sachs 40th Annual Global Healthcare Conference
  15. Edited Transcript of RVNC earnings conference call or presentation 8-May-19 8:30pm GMT
  16. Revance to Participate in the RBC Capital Markets 2019 Healthcare Conference
  17. Revance Reports First Quarter 2019 Financial Results and Provides Corporate Update
  18. A Spotlight On Revance Therapeutics, Inc.'s (NASDAQ:RVNC) Fundamentals